Abstract
This study analysed the outcome of 267 patients with relapse/refractory acute myeloid leukaemia (AML) who received sequential chemotherapy including fludarabine, cytarabine and amsacrine followed by reduced-intensity conditioning (RIC) and allogeneic haematopoietic stem cell transplantation (HSCT). The transplants in 77 patients were from matched sibling donors (MSDs) and those in 190 patients were from matched unrelated donors. Most patients (943%) were given anti-T-cell antibodies. The incidence of acute graft-versus-host disease (GVHD) of grades IIIV was 321% and that of chronic GVHD was 302%. The 3-year probability of non-relapse mortality (NRM) was 259%, that of relapse was 485%, that of GVHD-free and relapse-free survival (GRFS) was 178% and that of leukaemia-free survival (LFS) was 256%. In multivariate analysis, unrelated donor recipients more frequently had acute GVHD of grades IIIV [hazard ratio (HR)=198, P=0017] and suffered less relapses (HR=062, P=001) than MSD recipients. Treatment with anti-T-cell antibodies reduced NRM (HR=035, P=001) and improved survival (HR=049, P=001), GRFS (HR=037, P=00004) and LFS (HR=046, P=0005). Thus, sequential chemotherapy followed by RIC HSCT and use of anti-T-cell antibodies seems promising in patients with refractory AML.
Dokumententyp: | Zeitschriftenartikel |
---|---|
Fakultät: | Medizin |
Themengebiete: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit |
ISSN: | 0007-1048 |
Sprache: | Englisch |
Dokumenten ID: | 51911 |
Datum der Veröffentlichung auf Open Access LMU: | 14. Jun. 2018, 09:48 |
Letzte Änderungen: | 04. Nov. 2020, 13:30 |